There is a new clinical trial for men who struggle with pattern hair loss (PHL), a genetic disorder also known as androgenetic alopecia (AGA) – the most common form of hair loss in the world, which affects 80 million Americans alone.
The study at Johnson Dermatology is evaluating an investigational, non-hormonal oral tablet called VDPHL01. There are currently no FDA-approved treatments like this available and the call for better options is great. This is because available treatments have fallen short in addressing the needs of people coping with hair loss and thinning hair. What’s more, existing treatments are often accompanied by burdensome daily application of messy solutions and unwanted sexual and heart-related side effects.
“For too long, men have struggled with the emotional toll of pattern hair loss, having had to accept inadequate results and limited treatment options,” said Principal Investigator and Board-Certified Dermatologist, Sandra Johnson, M.D.“The initiation of this clinical trial is a major step forward due to the lack of novel and effective FDA drug approvals for hair loss in over two decades. Importantly, many of my patients have expressed wanting new treatments without the development of unwanted and sometimes serious side effects. New, clinically proven approaches can change their treatment journeys and improve outcomes for men who have been struggling to find better solutions.”
New clinical trial now enrolling
Dr. Johnson, who is leading the study in Fort Smith, is looking to enroll participants who are male between ages 18-65 and experiencing pattern hair loss.
In addition, participants must be in good general health; have normal liver and kidney function; be willing to maintain at least 1/4-inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; and maintain consistent use of general hair care products and regimen throughout the entire study. Trial participants will be compensated for their time and receive the study medication at no cost. Insurance is not required.
Also, the clinical trial will last 13 months with participants receiving either the study drug or placebo. At month six, all participants will receive the study medication for the remaining six months. Each visit will include health assessments and hair evaluations.
The trial is being sponsored by Veradermics, a biopharmaceutical company based in New Haven, Connecticut, that is developing VDPHL01.
If you are a man with pattern hair loss, Dr. Johnson encourages you to learn more about the potential benefits of the clinical trial by visiting www.phlstudy.com, calling (479) 649-3376 or contacting her clinic directly by email at study@johnsondermatology.com.
